173 related articles for article (PubMed ID: 8160629)
21. Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma.
Witzig TE; Maurer MJ; Habermann TM; Link BK; Micallef IN; Nowakowski GS; Ansell SM; Colgan JP; Inwards DJ; Porrata LF; Markovic SN; Johnston PB; Lin Y; Thompson C; Gupta M; Katzmann JA; Cerhan JR
Am J Hematol; 2014 Dec; 89(12):1116-20. PubMed ID: 25228125
[TBL] [Abstract][Full Text] [Related]
22. Three-color flow cytometry in the diagnosis of malignant lymphoma based on the comparative cell morphology of lymphoma cells and reactive lymphocytes.
Ichinohasama R; DeCoteau JF; Myers J; Kadin ME; Sawai T; Ooya K
Leukemia; 1997 Nov; 11(11):1891-903. PubMed ID: 9369423
[TBL] [Abstract][Full Text] [Related]
23. Distinct Dynamics of Mitotic Transition in B-Cell Lymphoma and Reactive B-Cell Lymphoproliferations Determined by H3S10 Phosphohistone Immunolabeling.
Méhes G; Hegyi K; Jobanputra R; Beke L; Vereb G; Bedekovics J
Pathobiology; 2017; 84(5):243-250. PubMed ID: 28715816
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
[TBL] [Abstract][Full Text] [Related]
25. Reactive T cells by flow cytometry distinguish Hodgkin lymphomas from T cell/histiocyte-rich large B cell lymphoma.
Wu D; Thomas A; Fromm JR
Cytometry B Clin Cytom; 2016 Sep; 90(5):424-32. PubMed ID: 26084540
[TBL] [Abstract][Full Text] [Related]
26. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype.
Delabie J; Vandenberghe E; Kennes C; Verhoef G; Foschini MP; Stul M; Cassiman JJ; De Wolf-Peeters C
Am J Surg Pathol; 1992 Jan; 16(1):37-48. PubMed ID: 1728195
[TBL] [Abstract][Full Text] [Related]
27. Fas ligand expression in nodal non-Hodgkin's lymphoma.
Müllauer L; Mosberger I; Chott A
Mod Pathol; 1998 Apr; 11(4):369-75. PubMed ID: 9578088
[TBL] [Abstract][Full Text] [Related]
28. DNA ploidy, proliferative activities, and immunophenotype of malignant lymphoma: application of flow cytometry.
Horii A; Yoshida J; Hattori K; Honjo Y; Mitani K; Takashima S; Sakai M; Okamoto S; Kubo T
Head Neck; 1998 Aug; 20(5):392-8. PubMed ID: 9663666
[TBL] [Abstract][Full Text] [Related]
29. [Long-term results with MACOP-B and radiation therapy for aggressive lymphomas].
Krieger G; Kreysing E; Kneba M
Onkologie; 2001 Feb; 24 Suppl 1():49-58. PubMed ID: 11441311
[TBL] [Abstract][Full Text] [Related]
30. [Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms].
Xiao C; Su ZL; Wu QL; Gao HY; Fang JC; Xia ZJ; Guan ZZ
Zhonghua Bing Li Xue Za Zhi; 2005 Jan; 34(1):22-7. PubMed ID: 15796877
[TBL] [Abstract][Full Text] [Related]
31. Characterization of malignant and non-neoplastic cell phenotypes in highly malignant non-Hodgkin lymphomas.
Porwit-Ksiazek A; Christensson B; Lindemalm C; Mellstedt H; Tribukait B; Biberfeld G; Biberfeld P
Int J Cancer; 1983 Dec; 32(6):667-74. PubMed ID: 6317576
[TBL] [Abstract][Full Text] [Related]
32. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease.
Carbone A; Gloghini A; Gruss HJ; Pinto A
Am J Pathol; 1995 Oct; 147(4):912-22. PubMed ID: 7573367
[TBL] [Abstract][Full Text] [Related]
33. Incidence, presenting features and prognosis of low-grade B-cell non-Hodgkin's lymphomas. Population-based data from a Danish lymphoma registry.
D'Amore F; Christensen BE; Thorling K; Pedersen M; Jensen MK; Boesen AM; Andersen E; Johansen P; Mortensen LS
Leuk Lymphoma; 1993 Dec; 12(1-2):69-77. PubMed ID: 8161937
[TBL] [Abstract][Full Text] [Related]
34. Practical utility of the revised European-American classification of lymphoid neoplasms for Japanese non-Hodgkin's lymphomas.
Izumo T; Maseki N; Mori S; Tsuchiya E
Jpn J Cancer Res; 2000 Mar; 91(3):351-60. PubMed ID: 10760696
[TBL] [Abstract][Full Text] [Related]
35. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
[TBL] [Abstract][Full Text] [Related]
36. Expression of the activation antigen, 4F2, by non-Hodgkin's lymphomas of B-cell phenotype.
Lewandrowski KB; Medeiros LJ; Harris NL
Cancer; 1990 Sep; 66(6):1158-64. PubMed ID: 1698116
[TBL] [Abstract][Full Text] [Related]
37. T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors.
Reiser M; Josting A; Soltani M; Staib P; Salzberger B; Diehl V; Engert A
Leuk Lymphoma; 2002 Apr; 43(4):805-11. PubMed ID: 12153168
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the proliferative index as a prognostic factor in diffuse large cell lymphoma: correlation with the International Index.
Ansell SM; Kurtin PJ; Stenson M; Habermann TM; Greipp PR; Therneau TM; Witzig TE
Leuk Lymphoma; 1999 Aug; 34(5-6):529-37. PubMed ID: 10492076
[TBL] [Abstract][Full Text] [Related]
39. Preferential expression of the mucosal homing receptor integrin alpha 4 beta 7 in gastrointestinal non-Hodgkin's lymphomas.
Drillenburg P; van der Voort R; Koopman G; Dragosics B; van Krieken JH; Kluin P; Meenan J; Lazarovits AI; Radaszkiewicz T; Pals ST
Am J Pathol; 1997 Mar; 150(3):919-27. PubMed ID: 9060830
[TBL] [Abstract][Full Text] [Related]
40. Immunophenotypic analysis of extranodal non-Hodgkin's lymphomas in the oral cavity.
Takahashi H; Fujita S; Okabe H; Tsuda N; Tezuka F
Pathol Res Pract; 1993 Apr; 189(3):300-11. PubMed ID: 8332573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
